Security key
04272N102
ArriVent BioPharma, Inc. - COMMON STOCK (AVBP)
CUSIP: 04272N102
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 29,075,127
- Total 13F value
- $539,323,391
- Share change
- +609,106
- SEC-reported price per share
- $18.49
- Number of holders
- 82
- Value change
- +$6,162,682
- Number of buys
- 42
- Number of sells
- 33
- Shares outstanding
- 49,367,935
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
82
Top holders
10
AVBP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
ArriVent BioPharma, Inc. SEC filings
ArriVent BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 04272N102
Recent filing periods:
Ownership snapshot
Top reported holders of AVBP - ArriVent BioPharma, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
HHLR ADVISORS, LTD.
Comparable rows
0/15
Latest evidence
31 Dec 2024
13F
3/4/5
Highest disclosed value: $119,471,662
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
HHLR ADVISORS, LTD. has the largest disclosed position value at $119.47M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens HHLR ADVISORS, LTD.'s linked filing trail.
Disclosed position value
Top 5
ORBIMED ADVISORS LLC
$80.65M
Carl L. Gordon
$5.52M
HHLR ADVISORS, LTD.
$119.47M
MONTANOVA CAPITAL, LLC
$59.83M
BlackRock, Inc.
$56.88M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
3/4/5
Company · Director, 10%+ Owner
|
—
denominator unverified
|
$80,648,018
3,027,328 shares
|
— | 31 Dec 2024 |
| Carl L. Gordon |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$5,524,874
1,513,664 shares
|
— | 30 Jan 2024 |
| HHLR ADVISORS, LTD. |
13F
Company
|
—
denominator unverified
|
$119,471,662
4,484,672 shares
|
— | 31 Dec 2024 |
| MONTANOVA CAPITAL, LLC |
13F
Company
|
—
denominator unverified
|
$59,833,440
2,246,000 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$56,878,851
2,135,092 shares
|
— | 31 Dec 2024 |
| Octagon Capital Advisors LP |
13F
Company
|
—
denominator unverified
|
$54,862,070
2,059,387 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
82
Shares
29,075,127
Rows available
82
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
82
Q1 2025 holders
82
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend